How pre-marketing data can be used for predicting the weight of drug interactions in clinical practice

Research output: Contribution to journalArticlepeer-review


Abstract Unexpected drug interactions have led to the withdrawal of many drugs, raising concern about the gap between what is known at the time of approval and the risk of serious effects in the longer term, particularly in high-risk populations generally excluded from drug development. This is because the majority of drug interaction studies are done using in vitro methods, or in healthy young volunteers who may not reflect the complexity of patients, and the settings in which the drug will be used in clinical practice. Pre-marketing interaction studies should therefore be designed to make information easily accessible and clinically transferable. They should be adequate in terms of sample size, population, comorbidity, phenotyping and/or genotyping, end-points and outcome measures, and conducted in conditions of dose, route and timing of co-administration that reproduce the proposed therapeutic indications of the new drug. Although young volunteers have the advantage of minimizing some confounding effects introduced by diseases or polypharmacy, patients drawn from populations for whom the drug is intended would be more relevant and accurate, providing the studies are feasible and safe.

Original languageEnglish
Pages (from-to)217-221
Number of pages5
JournalEuropean Journal of Internal Medicine
Issue number3
Publication statusPublished - Apr 2013


  • Clinical practice need
  • Drug-interactions
  • Pre-marketing information

ASJC Scopus subject areas

  • Internal Medicine


Dive into the research topics of 'How pre-marketing data can be used for predicting the weight of drug interactions in clinical practice'. Together they form a unique fingerprint.

Cite this